Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P 2008 New Zealand | April 2005-July 2007; 178 presentations of 156 patients with BZP toxicity, 69% with co-ingestions, most commonly ethanol;BZP serum levels drawn in 96 | prospective cohort | Symptoms of BZP toxicity; plasma BZP level correlation with seizure incidence; affect of co-ingestion with ethanol on seizure frequency or the incidence of other adverse side effects | Adverse effects include confusion, agitation, vomiting, anxiety, palpitations. Higher plasma levels of BZP are associated with increased incidence of seizures. Co-ingestion with ethanol has a negative association with seizure frequency, but is positively associated with an increased risk of confusion, agitation, and palpitations. | 1) This is the largest cohort of BZP users studied in a clinical setting, however, a larger sample size would have added further power to the analysis 2) Patients self reported the number of pills taken and co-ingestants used, creating recall bias 3) Plasma BZP levels were not taken at a consistent time after ingestion |
Gee P, Richardson S, Woltersdorf W, Moore G 2005 New Zealand | April 2005-Sept 2005, Patients presenting to the emergency department after ingesting herbal party pills containing 1-benzylpiperazine (BZP) | prospective cohort | Patterns of human toxicity related to the use of 1- (BZP)-based herbal party pills | 61 patients presented on 80 occasions. Average pills ingested for patients with adverse effects were 4.5. Mild to moderate toxicity: insomnia, anxiety, nausea, vomiting, palpitations, dystonia, and urinary retension. Seizures in 15. Life threatening toxicity in 2 patients, with status epilepticus and severe respiratory and metabolic acidosis. | This study was small, with an n=61. |